Retatrutide Weekly Update

Retatrutide Weekly Update

Maintained by the ThePeptide.ca Research Team · Updated weekly · Last updated: August 6, 2026 · Every item links to a verified primary source and is labelled by evidence type.

Current status · as of August 6, 2026

Retatrutide (LY3437943) is an investigational triple GIP/GLP-1/glucagon receptor agonist. It is not approved by Health Canada, the FDA, or any other regulator. Eli Lilly has completed five positive Phase 3 readouts across the TRIUMPH and TRANSCEND programs and has stated it plans to file for FDA approval in 2027. One Phase 3 dataset — TRANSCEND-T2D-1 — has cleared peer review in The Lancet; the remaining figures circulating publicly come from company press releases. In August 2026, Lilly opened a narrow US expanded-access (compassionate-use) pathway allowing a limited number of patients who cannot enrol in a trial to request the drug before approval; this is not an approval and does not apply in Canada. In Canada, retatrutide has no Drug Identification Number and may not be sold or marketed for human use.

Compound reference

Compound Retatrutide (LY3437943)
Class Triple receptor agonist — GIP / GLP-1 / glucagon
Molecular formula C221H342N46O68
Molecular weight 4,731.42 g/mol
CAS number 2381089-83-2
PubChem CID 171934787 (indexed as retatrutide sodium salt)
Regulatory status Investigational. No Health Canada DIN. No FDA approval. Filing anticipated 2027.
Registrational program TRIUMPH (obesity, knee OA, sleep apnea) and TRANSCEND (type 2 diabetes, CKD)
Research Use Only This page reports outcomes published in clinical trials, company releases and regulatory notices, presented for scientific reference only. Nothing here is medical, legal or regulatory advice, a dosing recommendation, or an encouragement to use any substance for human consumption. ThePeptide.ca supplies materials strictly for laboratory and in-vitro research use. Retatrutide is not approved by Health Canada or the FDA and is not for human or veterinary use.

How to read this page

Every item is tagged with the type of evidence behind it, because a company press release and a peer-reviewed publication are not the same thing — and most coverage of this compound does not distinguish them.

Peer-reviewed Published in a journal after review.
Company release Sponsor-reported topline data, not yet peer-reviewed.
Regulatory Action or notice from a regulator or court.
Conference Presented at a scientific meeting.
Analysis Secondary reporting or expert commentary.

A recurring caution: retatrutide weight-loss figures vary between sources because trials report two estimands — an efficacy estimand (effect if participants stayed on treatment) and a treatment-regimen estimand (effect across everyone randomised). Where both are known, this page reports both. A figure quoted without an estimand label and a timepoint should be treated as unsourced.
Filter by week

Weekly log

Lilly opens narrow pre-approval access to retatrutide amid physician pushback

Week of Aug 3 – 9, 2026
TL;DR

Eli Lilly confirmed on August 3, 2026 that it will let a limited number of patients apply for retatrutide before FDA approval through an expanded-access (compassionate-use) pathway, subject to narrow eligibility criteria. No new efficacy or safety data were released; retatrutide remains investigational and unapproved everywhere, and the pathway is a US mechanism that does not apply in Canada.

Company statementLilly formalises a limited expanded-access program

In statements to reporters on August 3, 2026, Lilly said it would allow patients who cannot enrol in a clinical trial to request retatrutide ahead of FDA approval. A company spokesperson said: “For a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial, we believe it is medically appropriate to make authentic retatrutide available before FDA approval, consistent with FDA's guidance.” Reported eligibility criteria are: age 18 or older; severe obesity unresponsive to the maximum approved doses of existing obesity medication; at least two serious or life-threatening obesity-related complications requiring medical care; and inability to participate in ongoing retatrutide or comparable investigational trials. This was a statement confirmed to the press rather than a formal press release or peer-reviewed report, and Lilly still plans to file for FDA approval in 2027.

Source: STAT News · Reuters (syndicated)

AnalysisClinician reaction is mixed; criteria are narrow

The move follows June 2026 STAT reporting that Lilly had granted a single 79-year-old patient compassionate-use access in April 2026, which prompted other physicians — including Spencer Nadolsky and Mike Albert — to say their own access requests had gone weeks without a substantive response. Coverage this week noted the published criteria are strict enough that most patients seeking the drug would not qualify. No clinical outcome from any expanded-access use has been reported, and none should be inferred; this is an access-policy development, not new trial evidence.

Source: AJMC

Canadian enforcement lands; filing timeline digested

Week of Jul 27 – Aug 2, 2026
TL;DR

Health Canada publicly announced a permanent court injunction against a Canadian online peptide retailer — the first Canadian enforcement development of this scale to touch the compounds named in its April advisory, retatrutide among them. No new retatrutide trial data this week; coverage focused on digesting Lilly’s 2027 filing timeline.

RegulatoryHealth Canada announces permanent injunction against Canlab Research

The Superior Court of Québec granted the injunction on June 11, 2026; Health Canada announced it publicly in late July. It permanently bars the company from selling unauthorized injectable peptides and from advertising them “including through any website or social media platform accessible with a Canadian Internet Protocol (IP) address.” Retatrutide was among the compounds named in Health Canada’s April 9, 2026 advisory.

Source: Health Canada news release · Our full analysis: FDA & Peptides in 2026

AnalysisCoverage frames the 2027 FDA filing as a delay

Following Lilly’s July 23 confirmation that it will file for FDA approval in 2027, several outlets characterised the timeline as a delay against earlier expectations. No change to the underlying data was reported; the compound remains investigational everywhere.

Source: CNBC · BioPharma Dive

TRIUMPH-2 and TRIUMPH-3 read out; Lilly commits to a 2027 filing

Week of Jul 20 – 26, 2026
TL;DR

Lilly reported topline results from two more Phase 3 obesity trials, completing the core weight-loss dataset, and said it will seek FDA approval in 2027. The cardiovascular readout in TRIUMPH-3 was neutral, not protective — a limitation worth stating plainly.

Company releaseTRIUMPH-2 and TRIUMPH-3 topline results

TRIUMPH-2 (type 2 diabetes with obesity, n≈1,152) reported 20.8% weight reduction at 12 mg over 80 weeks versus 4.0% on placebo, with A1C down 1.6%. TRIUMPH-3 (severe obesity with established cardiovascular disease, n≈1,949) reported 22.6% versus 3.2% on placebo.

Source: Eli Lilly investor release, July 23, 2026

Company releaseCardiovascular outcome was neutral, not protective

TRIUMPH-3 recorded 44 major adverse cardiovascular events in the retatrutide arms versus 52 on placebo — a five-point MACE hazard ratio of 0.82 (95% CI 0.55–1.22). The confidence interval crosses 1.0, so the result is not statistically significant; Lilly noted events occurred less frequently than anticipated in both arms. Cardiovascular risk factors improved clearly at 12 mg (triglycerides roughly −37%, non-HDL cholesterol −16.5%, hs-CRP −51.2%). The larger TRIUMPH-Outcomes study is designed to answer the events question.

Source: Fierce Biotech

First peer-reviewed Phase 3 dataset published in The Lancet

Week of Jun 1 – 7, 2026
TL;DR

TRANSCEND-T2D-1 became the first retatrutide Phase 3 dataset to clear peer review, published in The Lancet and presented at the ADA Scientific Sessions. This is the single most citable retatrutide result to date.

Peer-reviewedTRANSCEND-T2D-1 published in The Lancet

In 537 adults with type 2 diabetes across 48 sites over 40 weeks, once-weekly retatrutide reduced HbA1c by 1.94% at 12 mg from a baseline mean of 7.9%, versus 0.81% on placebo (difference 1.12%, P<0.0001); 82–89% of participants reached HbA1c below 7.0%. Mean weight reduction reached 15.3% (15.1 kg) versus 2.6% on placebo. Gastrointestinal adverse events were mild to moderate; no severe hypoglycaemia was reported.

Source: The Lancet, doi:10.1016/S0140-6736(26)00967-0 (online June 6, 2026)

ConferenceTRIUMPH-1 and TRANSCEND-T2D-1 presented at ADA 2026

Both datasets were presented at the American Diabetes Association 86th Scientific Sessions on June 6, 2026, in New Orleans. TRIUMPH-1 secondary outcomes reported included 65.3% of participants reaching BMI below 30 at the 12 mg dose.

Source: Cleveland Clinic Journal of Medicine, ADA 2026 coverage

TRIUMPH-1 pivotal obesity results reported

Week of May 18 – 24, 2026
TL;DR

The pivotal obesity trial reported up to 28.3% mean weight reduction at 80 weeks under the efficacy estimand — the headline number most widely quoted since. Lilly reported both estimands; most coverage quotes only the larger one.

Company releaseTRIUMPH-1 topline: both estimands reported

In 2,339 randomised participants over 80 weeks, mean weight reduction was:

Dose Efficacy estimand Treatment-regimen estimand
12 mg −28.3% (−70.3 lb) −25.0% (−62.1 lb)
9 mg −25.9% (−64.4 lb) −23.7% (−58.9 lb)
4 mg −19.0% (−47.2 lb) −17.6% (−43.7 lb)
Placebo −2.2% (−5.5 lb) −3.9% (−9.7 lb)

The widely quoted 30.3% figure is an efficacy-estimand result at 104 weeks in the 532 participants with BMI ≥35 who continued into a pre-specified extension — not the whole trial population at 80 weeks.

Source: Eli Lilly release, May 21, 2026

Company releaseTolerability: discontinuation rose with dose

Discontinuation due to adverse events was 4.1% (4 mg), 6.9% (9 mg) and 11.3% (12 mg), versus 4.9% on placebo. Nausea was the most common adverse event at 42.4% on 12 mg versus 14.8% on placebo, alongside diarrhoea, constipation and vomiting.

Source: The Pharmaceutical Journal

First Phase 3 readout — and a new safety signal

Week of Dec 8 – 14, 2025
TL;DR

TRIUMPH-4 was the first Phase 3 trial to report, combining substantial weight reduction with large knee-osteoarthritis pain improvements. It also surfaced dysesthesia — a safety signal that had not appeared in Phase 2 and remains under-reported in most coverage.

Company releaseTRIUMPH-4: 28.7% weight reduction with knee osteoarthritis

In 445 adults with obesity or overweight plus knee osteoarthritis and without diabetes (BMI ≥27; baseline mean 112.7 kg), 68 weeks of retatrutide at 9 mg or 12 mg produced up to 28.7% mean weight reduction (−32.3 kg / −71.2 lb). Roughly half of participants achieved at least 25% reduction.

Source: Eli Lilly release, December 2025

Company releaseKnee pain outcomes

WOMAC pain scores fell by up to 4.5 points (−75.8%) versus 2.4 points (−40.3%) on placebo. Approximately one in eight retatrutide-treated participants reported being completely free of knee pain, versus just over 4% on placebo. WOMAC function subscale improvements exceeded 70%.

Source: Patient Care Online

AnalysisNew dysesthesia signal not seen in Phase 2

Dysesthesia — an abnormal sense of touch in which normal sensations feel unusual or painful — occurred in 8.8% at 9 mg and 20.9% at 12 mg, versus 0.7% on placebo. Lilly reported that these events did not appear to lead to discontinuation. The signal had not emerged in Phase 2 testing. Overall discontinuation in TRIUMPH-4 was 12.2% (9 mg) and 18.2% (12 mg) versus 4.0% on placebo.

Source: BioSpace

No entries for that week.

The trial programs, in brief

Retatrutide is being studied across two registrational programs. Keeping them straight matters, because coverage frequently conflates them.

Program Focus Trials referenced to date
TRIUMPH Obesity, knee osteoarthritis, obstructive sleep apnea TRIUMPH-1 (obesity), TRIUMPH-2 (T2D with obesity), TRIUMPH-3 (severe obesity with CVD), TRIUMPH-4 (knee OA), TRIUMPH-Outcomes (cardiovascular events)
TRANSCEND Type 2 diabetes and chronic kidney disease TRANSCEND-T2D-1 (published), TRANSCEND-CKD (design published)

Program design details are published in the peer-reviewed literature: PMID 41090431 (TRIUMPH rationale and design) and PMID 41160422 (TRANSCEND-CKD).

Retatrutide and Canadian law

Retatrutide is not authorized for sale in Canada. It has no Drug Identification Number, and Health Canada regulates injectable peptides of this kind as prescription drugs under the Food and Drugs Act. Health Canada has stated explicitly that “research use only” labelling does not make such products legal or exempt them from regulatory requirements. Materials supplied for laboratory research are a separate category and are not for human use.

Full context: FDA & Peptides in 2026: the PCAC vote, retatrutide’s Phase 3 data and what’s legal in Canada.

Update log. July 31, 2026 — Page created. Launch archive covers the week of Jul 27 2026 back to the first Phase 3 readout in Dec 2025, with all figures verified against primary sources and both TRIUMPH-1 estimands reported. August 6, 2026 — Added the week of Aug 3, 2026: Lilly opened a limited pre-approval expanded-access pathway for retatrutide; no new trial data this week. Current-status block updated to note the expanded-access pathway.

Final disclaimer — research use only This page is informational and educational and does not constitute legal, medical or regulatory advice. Clinical figures are outcomes reported by trial sponsors or published journals and are presented for scientific reference only; they are not dosing guidance and not a claim about any product sold by ThePeptide.ca. Regulatory status is summarised as of the last-updated date above and can change — verify against primary sources. All products sold by ThePeptide.ca are intended strictly for laboratory and in-vitro research, are not approved by Health Canada or the FDA, and are not for human or veterinary consumption.